The Fool notes here that they own shares of Mela Sciences. This stock is risky right now since their Melanoma device did not get approved by the FDA in July. The FDA needed more information and will make a decision in November.
Many expect that the FDA will approve the device, since it only emits light waves and does not inject a drug into the human body. Once analyst also seems optimistic since he recently upgraded shares with a $9.00 target price.